vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
04 août 2021 16h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the...
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
05 mai 2021 16h10 HE
|
vTv Therapeutics Inc.
Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of...
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
13 avr. 2021 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
12 avr. 2021 16h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
23 mars 2021 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods...
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
18 mars 2021 16h05 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
Digital Diabetes Management Market Size & Share 2021-2027 | North America, Europe, & APAC Industry Forecasts: Graphical Research
09 mars 2021 06h30 HE
|
Graphical Research
Pune, India, March 09, 2021 (GLOBE NEWSWIRE) -- The digital diabetes management market size is predicted to expand at significant CAGR during the forecast period, with the need for accurate,...
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
08 mars 2021 16h05 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
24 févr. 2021 16h30 HE
|
vTv Therapeutics Inc.
Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1...
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
23 févr. 2021 10h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...